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Abstract
Background: Virtual Reality Exposure Therapy (VRET) is found to be a promising and a viable alternative for in vivo
exposure in the treatment of specific phobias. However, its usefulness for treating dental phobia is unexplored. The
aims of the present study are to determine: (a) the efficacy of VRET versus informational pamphlet (IP) control
group in terms of dental trait and state anxiety reductions at 1 week, 3 months and 6 months follow-up (b) the
real-time physiological arousal [heart rate (HR)] of VRET group participants during and following therapy (c) the
relation between subjective (presence) and objective (HR) measures during VRET.
Methods: This study is a single blind, randomized controlled trial with two parallel arms in which participants will be
allocated to VRET or IP with a ratio of 1:1. Thirty participants (18-50 years) meeting the Phobia Checklist criteria of dental
phobia will undergo block randomization with allocation concealment. The primary outcome measures include
participants’ dental trait anxiety (Modified Dental Anxiety Scale and Dental Fear Survey) and state anxiety (Visual
Analogue Scale) measured at baseline (T0), at intervention (T1), 1-week (T2), 3 months (T3) and 6 months (T4) follow-up.
A behavior test will be conducted before and after the intervention. The secondary outcome measures are real-time
evaluation of HR and VR (Virtual Reality) experience (presence, realism, nausea) during and following the VRET
intervention respectively. The data will be analyzed using intention-to-treat and per-protocol analysis.
Discussion: This study uses novel non-invasive VRET, which may provide a possible alternative treatment for dental
anxiety and phobia.
Trial registration number: ISRCTN25824611, Date of registration: 26 October 2015.
Keywords: Dental phobia, Virtual reality exposure therapy
Background
It is estimated that as many as 75 per cent of US adults
experience some degree of dental anxiety, from mild to se-
vere [1, 2] and that 50-60 % of individuals suffer from a
specific fear of dental procedures and dental related stim-
uli [3]. Given that dental phobia belongs to the most com-
mon phobic conditions in our society, finding a suitable
specific non-invasive strategy to reduce dental anxiety and
treat dental phobia is both warranted and important.
Exposure based treatment programs are considered as
the gold standard in the treatment of specific fears and
phobias [4–6], including those related to the dental treat-
ment situation [7], [8, 9]. However, potential drawbacks
include: (a) the difficulty for patients to mentally visualize
the anxiety inducing threat as in imaginal exposure ther-
apy [10], (b) the unwillingness of patients to face the ac-
tual threat in in vivo exposure therapy (IVET) resulting in
refusal or termination of therapy accounting for 25 % [11],
(c) the failure to achieve clinically significant symptom re-
lief, and return of fear, following exposure therapy [12],
(d) the poor availability of psychological services [13] and
(e) the high costs [14] involved with this treatment.
Recently, VRET has become a viable alternative for in
vivo exposure in the treatment of fears and specific
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phobias [15] including claustrophobia [16], acrophobia
[17], fear of flying [18], and spider phobia [19]. This in-
volves conducting exposure therapy using computer
generated Virtual Reality (VR) environments by system-
atic confrontations of patients with their potentially fear-
provoking (i.e., ‘conditioned’) stimuli so that habituation
occurs [15, 17]. Compared to IVET, VRET is safer be-
cause the patients faces the virtual representation of
their threat more gradually in a controlled manner, and
at their own pace [10]. As the entire exposure process in
VRET is completed under privacy of therapists’ office it
may elicit less fear of social embarrassment to the pa-
tients [20] . VRET can be repeated, whenever and, for as
many times [10] as necessary without incurring any add-
itional costs. In-vivo exposure therapy requires training
on the part of therapist and is usually delivered by
trained psychologists. Compared to this, administration
of VRET may just require a working knowledge of
computer operation and basic training to operate the
apparatus.
VRET is known to elicit a feeling of being “present” in
the virtual environment [15, 17]. This sense of presence
is considered to be the essence for the effectiveness of
VR [21] and has been found to be an important mediat-
ing variable [15] between the VR media and the level of
anxiety induced [22]. Presence in VR is measured sub-
jectively with questionnaires or objectively with physio-
logical measures [e.g., heart rate (HR), body posture,
skin conductance level] [15, 17]. VRET was found to be
able to elicit physiologic responses in individuals with fear
of flying phobia (measured by HR and skin-conductance)
when exposed to VR flights, and these responses de-
creased following repeated VR exposure flights [23]. Psy-
chophysiological arousal forms the basis for an effective
exposure based therapy [24]. A recent systematic review
has suggested that VRET does elicit psychophysiological
arousal, thereby rendering it to be a promising treatment
modality for treatment of anxiety disorders [25]. However,
the effect of VRET on HR is inconclusive because of lim-
ited well designed studies [25]. Also, there is no published
research examining the role of VRET in causing psycho-
physiological arousal in anxious dental patients. Further,
studies examining the relationship between subjective
presence and physiological responses are limited [26].
A recent meta-analysis suggests VRET to be slightly,
but significantly, more effective than IVET (in vivo ex-
posure therapy) [27]. Although, VRET provides a power-
ful means of modifying affect, because of its immersive
nature, it has not been tested yet as a therapy for den-
tally related anxiety or dental phobia. In an effort to
answer this question, we will use VRET simulation soft-
ware for the treatment of dental phobia and test its effi-
cacy in the present study. The primary objective of the
present study is to determine the efficacy of VRET
versus an informational pamphlet control group in
terms of dental trait and state anxiety reductions at
1 week, 3 months and 6 months follow-up among a
sample of patients suffering from dental phobia. The
secondary objectives are to determine (a) the real-
time effect of VRET on the course of participant’s
physiological response (HR) on exposure with a
series of dentally related cues during therapy and (b)
the relation between subjective (i.e., presence) and
more objective (i.e., HR) measures during VRET. It
is hypothesized that: (a) VRET would result in a
significantly reduced level of dental trait anxiety
[measured by MDAS (Modified Dental Anxiety
Scale) and Dental Fear Survey (DFS)] and state
anxiety [indexed by VAS-A (Visual Analogue Scale-
Anxiety)] at 1 week, 3 months and 6 months follow-
up compared to the informational pamphlet control
group, (b) VRET would result in significantly higher
reduced physiological arousal (i.e., HR) to dental
anxious stimuli/cues relative to the baseline HR
values following therapy, (c) VRET will demonstrate
a positive correlation between subjective and object-
ive measures of ‘presence’.
Methods
Trial design
The study will be conducted in compliance with local
regulations and internationally established principles
of the declaration of Helsinki (64th World Medical
Association General Assemble, Fortaleza, Brazil, 2013).
The study and protocol were approved by the Ethics
Commission of the SEGi University (Reference: EC01/
14-01). This VRET study will be designed as a single
blind (Biostatistician will be blinded), randomized
controlled trial with two parallel arms: VRET and
Informational Pamphlet (IP) groups with an allocation
ratio of 1:1 as shown in Fig. 1. Thirty participants
undergo block randomization so that we have equal
distribution of participants in both the groups. In
order to preserve the allocation concealment, we will
be using, sealed, opaque, sequentially numbered envelopes
(SNOSE); [28]. Envelopes will be opened serially (next
highest number) only after the participant details (patient
unique number, date and patient signature) are entered on
the envelope. Carbon paper inside the envelope enables
transfer of details to the assignment card. Cardboard or
aluminum foil inside the envelope renders the envelope
impermeable to intense light [29].
The two groups are assessed at baseline (T0), before
and after intervention (T1), at 1-week follow-up (T2),
3 months after treatment (T3) and 6 months after treat-
ment (T4) on a set of variables that are linked to the
various research questions. The participant flow and
timing of evaluation is depicted in Fig. 1.
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Participants
Adult outpatients who have not visited the dentist since
last 12 months or those reporting with anxiety and
avoidance of dental procedures will be screened and re-
cruited from the outpatient service of Oral Health
Centre of faculty of Dentistry, SEGi University at
Malaysia. The trial process starts with a short self-report
assessment with a MDAS questionnaire to screen for
possible dental phobia. Interested participants, who
agreed to participate in our VRET Dental Phobia study,
with a MDAS score of ≥15, will be contacted and given
an appointment by the researcher for an interview. A
screening tool, the “Phobia Checklist” [30] will be used
for the assessment of dental phobia in this study. This
measure for assessing dental phobia has previously been
validated against the Structured Clinical Interview for
DSM-IV with a sensitivity of 0.95, specificity of 0.99, and
an overall hit rate of 97 %. The phobia checklist consists
of four questions based on the DSM-IV-TR [31]criteria
for specific phobia. The patients are requested to mark
either a ‘YES’ or ‘NO’ response to the following ques-
tions related to their dental anxiety:
a. The sight of the feared object or experiencing the
situation evokes an excessive fear response.
b. The fear is greater than justified.
c. Avoidance or giving up things because of the fear.
d. Avoidance of the situation or object causes daily
impairment.
An individual is categorized as dental phobic only
upon answering ‘YES’ against all four questions of the
Fig. 1 Participant flow and timing of evaluation
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phobia checklist. In the present study, the checklist will
be administered during the screening interview and at
6 month follow-up.
Anticipated timeline for this study will be as follows:
1. Enrollment to Inclusion Interview: Maximum 1 week.
2. Inclusion Interview to Baseline, Randomization &
Allocation: Maximum 1 week.




Participants should satisfy all criterion for inclusion.
– Meeting the criteria of “Phobia checklist”.
– An age between 18 to 50 yr.
– Any dental phobic patient requiring the following
planned dental treatment/s of at least 30 minutes
per appointment.
1. Restorative dental procedure which may or may
not be requiring local anesthesia.
2. Extraction procedure requiring local anesthesia.
The participants will be recruited from the out-patient
department of the oral health Centre where it is
mandatory for every patient to undergo a diagnostic
examination. The information about treatment needs
will be obtained from the findings of the diagnostic
examination.
Exclusion criteria
Presence of any criteria mentioned below result in exclu-
sion of the participant.
– Hearing or visual impairment such as stereoscopy
blindness or nystagmus.
– Known mental disorders such as psychosis,
post-traumatic stress disorder, developmental or
intellectual disability and cognitive impairment.
– Known balance disorders such as vertigo and
cybersickness.
– Patients with previous history of epileptic seizures.
– Any history of cardiac problems.
– Patients who are undergoing, or have undergone,
any cognitive behavioral therapy (CBT)-based
intervention for dental phobia.
– Language impediment (cannot understand English).
– Patients wearing glasses of greater than plus 3.5
power.
Outcome measures
Table 1 and 2 provide an overview of the measures at
various time points. Participants of both groups are
evaluated using a series of measures as mentioned
below. The participants of the VRET group will
undergo HR monitoring in real time, assessed for
subjective discomfort/distress and evaluated for VR
experience at T1 during the intervention as depicted
in Table 1 and 2.
Primary outcome measures
Anxiety Will be determined utilizing VAS-A, MDAS
and DFS survey.
– Visual analogue scale for state anxiety (VAS-A) [32].
VAS-A will be recorded by asking the participants
to draw a cross mark (X) on a 0-100 mm horizontal
scale with the extreme left edge of the scale indicating
feeling totally calm and relaxed (0) and the extreme
right edge, feeling the worst fear imaginable (100).
The measured distance from the left edge of the line
to the cross mark placed by the participants to the
nearest millimeters provides a quantitative variable
that can be used in statistical analysis. The VAS-A has
been found to be a simple, sensitive, fast, reliable and
valid tool to measure level of state anxiety [33].
– Modified Dental Anxiety Scale [34]. The Modified
Dental Anxiety Scale (MDAS; Humphris 1995) is a
5-item scale assessing dental (trait) anxiety. Respon-
dents are asked to rate their level of anxiety across
five different scenarios (e.g., anxiety response on a
previous day to a prospective dental visit, when in
the waiting room, when about to have tooth drilled,
teeth scaled and injection to the gums) on a 5-point
Likert scale ranging from “not at all anxious” to
“extremely anxious”, and possible scores range from
5 to 25, with greater scores indicating higher level of
dental anxiety. The MDAS shows high levels of
internal consistency and good construct validity [35].
– Dental Fear Survey [36]. The Dental Fear Survey
(DFS; Kleinknecht 1973) is a 20-item measure used
to identify emotional and physiological reactions
associated with several aspects of dentistry, as well
as avoidance of dental care due to anxiety.
Possible scores range from 20 to 100, with
greater scores indicating higher levels of dental
anxiety. The DFS has established reliability,
validity and sensitivity [37].
Behavioral avoidance test A Behavioral avoidance test
will be done prior to, and immediately after, the inter-
ventions at T1 by means of standardized observation of
behaviour, and an interview for both the groups. The
test is similar to the VRET scenarios, and provides a
baseline behavioral assessment measure to compare the
responses of the patient before and after the VRET. This
in vivo test represents an observer-rated instrument
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earlier used by Doering et al. [38]. It contains 5 situa-
tions that occur during a dental visit (e.g., sitting in the
dental chair, inspection of the oral cavity using dental
mirrors, approaching dental syringe, approaching dental
drill without sound and approaching dental drill with
sound). While the patient undergoes the dental visit it is
observed whether he/she is able to tolerate the situation,
and he/she is asked by the observer to assess his/her
level of anxiety on a scale of 0–10 in each situation. Both
observation and answers to the standardized questions
are recorded during the procedure.
Secondary outcome measures
a) Psychophysiological parameter: A heart rate wrist
band will be used to record the real time response to
VRET at T1 during VRET session. The device will be
integrated with the VR software and the output will
be recorded during therapy.
b) Subjective Units of Distress (SUD) scale: The SUD
scale is an eleven-point scale [39] to measure the
intensity of subjective distress currently experienced
by an individual. It is used by the therapist in
desensitization based therapies as a standard to
evaluate the progress of the therapy. Typically the
patient is asked by the therapist “On a scale of 0-10
where, 0 is no discomfort and 10 is the worst, how
do you feel right now”. The researcher will record
the SUDS scores during each VR scenario exposure
of the VRET session. During the VRET session each
VR exposure is repeated, until there is habituation
demonstrated by a relatively low SUD score (≤2),
and the next scenario is introduced. The total
number of VR exposures with each VR scenario that
was required to achieve SUDS score of ≤2 will be
summed up and recorded by the researcher
post-therapy.
c) VR experience: will be evaluated at T1.
– Time perception is determined by asking the
participants to calculate approximately the
duration of VR immersion with therapy [40] and
the ratio of subjective and objective duration will
be evaluated.
– Presence will be measured using an 11-point
verbal rating scale (VRS) [41].
– Realism will be indexed with an 11-point
(VRS) [41].
– Severity of nausea (‘cybersickness’) will be
measured using an 11-point VRS [41].
– Intention to use VR goggles again will be indexed
with a yes/no response.
– Intention to revisit the dental surgery will be
measured with a yes/no response.
Procedure
After arrival at the dental office, participants will receive a
detailed explanation about the study from the researcher.
All participants will be asked for a written informed con-
sent to participate in the study. The participants will be
interviewed to screen for dental phobia using the “Phobia
checklist” by the researcher. The interview will take 0.5 to
1.5 hours. The participants will undergo the baseline
assessments (T0) which will include use of questionnaires
to record the participants’ characteristics such as
demographic information, self-reported oral health, self-
reported dental attendance and history of a bad experi-
ence with a previous dentist [42]. Completing the ques-
tionnaires will take 10-15 minutes. The interview and
questionnaire are completed on the same day. Informed
consent and pre-operative data will be collected in the
waiting area. The participants undergo VRET at their own
pace free of cost. The assessment of state and trait dental
anxiety will be done utilizing the VAS-A [32], MDAS [34]
and DFS [36]. After T0, the participants will be block ran-
domized as mentioned in Fig. 1 into VRET intervention
and informational pamphlet control groups.
Table 1 Showing overview of measures at different time periods
Measurements















Baseline (T0) Screening interview X X X - - - -
Intervention (T1) Preoperative interview X X X X - - -
VRETa session or IPb - - - - X X X
Postoperative interview X X X X - - -
Follow-up (T2,T3) E mail X X X - - - -
Follow-up (T4) E mail X X X - - - -
Note: ‘X’ Indicates timing of measurement of the outcome measures
aVRET: Virtual Reality Exposure Therapy
bIP: Informational Pamphlet
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(Drill with no sound)
Scenario #5
(Drill with sound)
1 Number of exposures 1 2 3 4 p 1 2 3 4 q 1 2 3 4 r 1 2 3 4 s 1 2 3 4 t X
2 Subjective measure(SUDS) X X X X X X X X X X X X X X X X X X X X X X X X X X
3 Subjective measure(Presence) X - - - - X - - - - X - - - - X - - - - X - - - - X
4 Subjective measure(Realism) X - - - - X - - - - X - - - - X - - - - X - - - - X
5 Subjective measure(Nausea) X - - - - X - - - - X - - - - X - - - - X - - - - X
7 Objective measure(HR) X X X X X X X X X X X X X X X X X X X X X X X X X X X X














Description of the VRET system used
The VRET software has been developed for this study by
Virtual Simulations Inc in collaboration with KR and
ADJ. The hardware comprises of two networked
computers of which the VR-simulator PC (Personal
Computer) renders the virtual environment and the
other User interface-PC (UI-PC) allows the therapist to
control and individualize stimuli presented. The VR-
simulator software will generate the VR dental envir-
onment using a Dell XPS-8700 desktop with 4th
Generation Intel Core i7-4790 processor (8 M Cache,
up to 4.0 GHz) and ASUS NVIDIA GEFORCE GTX
750 TI OC 2GB GDDR5 graphic card. The system
will generate the display at a rate of 60 frames per
second. To immerse the participants in the VR dental
environment we will use an Oculus development kit 2
HMD (Head Mounted Display) with a resolution of
960X1080 per eye and with a 100 degree field of view
(nominal).
Treatment room configuration
The waiting and VR treatment area will be shaped, using
cues usually present in these areas. For VRET, a simu-
lated dental environment will be created, with a dental
chair, overhead light, dental instruments and to enhance
immersion characteristic dental clinic-related smell
(drops of oil of cloves on cotton wool) will be introduced.
The room temperature will be maintained at 21 °C.
The treatment room where the study will be con-
ducted will be equipped with:
1. Two networked computers and a HMD as described
above.
2. Oculus positional tracking camera mounted on a
tri-pod: To track the head movements in real-time.
3. Logitech C-920C webcam mounted on a tri-pod: To
record the video for future validations and evaluate
the participant’s body response during VRET.
4. YOGA Mini Tie Clip Condenser Microphone: To
record the voice of the participants during VRET, It
is synchronized with the webcam.
5. MIO LINK HR wrist band: To record the real-time
HR of the participants during therapy.
6. SUUNTO movestick mini: For wireless transfer of
HR data from the wrist band to the simulator PC.
7. PHILIPS wireless portable speaker BT100B/37: To
produce characteristic dental drill sound.
The simulated dental experience
The VRET system will be operated by the author of this
study. Training will be provided by a clinical psycholo-
gist and Virtual Simulations Inc. When participants
assigned for VRET visit the dental office the researcher
records the unique reference number and initiates the
VRET session. The Simulator PC, UI PC and video cam-
era are turned on. Participants will be seated in a supine
position comfortably in the dental chair and will be
assisted in wearing the HMD (in OFF mode) and HR
bracelet (left hand) by the researcher. Also, a hand held
computer mouse will be given to the participants which
acts as a panic button. The participants will hold the
computer mouse with their right hand and will be
instructed how to activate the panic button by clicking
the mouse (under their control) when the presented sce-
nario feels unbearable to them during the VRET session.
The simulator PC is connected with the UI PC. On the
UI window the researcher enters the patient/subject
name, connects the UI with VR simulator by entering
VR Internet Protocol address and presses the start but-
ton of the log record for real time HR recording con-
tinuously during the session.
Phases of VRET session: The phases are depicted in Table 2
Baseline phase During this phase, the participants will
see no display (Black screen) through the HMD (In OFF
mode) for 10 minutes. Concurrently, the VR simulator
software will record the HR. The purpose will be to rec-
ord the resting HR as per HR wrist band manufacturer’s
instructions.
Training phase The HMD is turned ON once during
the entire VRET session at this phase. In general, partici-
pants may show a higher physiological response when
exposed to see something novel, this is referred to as
orientation effects [43]. To overcome this, the partici-
pants in this phase will first view a surrounding 3D (3
Dimensional) stereoscopic scene of simulated dental en-
vironment through the HMD and only take a passive
role by watching the interactive scene for 2 minutes.
The participants are encouraged to turn his head and
look around the virtual dentist’s office by way of the
built-in motion tracking present in the HMD. Thus, the
test subject will be lying on a real dentist chair while he
will see its virtual counterpart inside the HMD as he
looks around, turning his head. To allow the test subject
to feel immersed in the virtual environment, we will in-
clude a generic 3D model of a person lying on the den-
tist chair such that when looking down, the subject will
see what feels like his own body. The virtual environ-
ment seen by the patient will be displayed to the re-
searcher on the computer screen and the HR will also
be recorded.
Experimental phase In this phase, participants are ex-
posed to five different VR scenarios (Idle, Mirror, Syr-
inge, Drill with no sound, Drill with sound). The
duration of each exposure will be 35 seconds. The
Raghav et al. BMC Oral Health  (2016) 16:25 Page 7 of 11
interactive part of the simulated dental environment will
be controlled by the researcher using the tool selection
option on the UI window of the computer. The re-
searcher will be able to control the playback of the VR
scenarios.
VRET is conducted using a pre-determined hierarchy
as follows:
1. Scenario #1 (Idle). This shows a dental operatory
with various instruments surrounding the patient’s
chair and a virtual dentist sitting next to the
patient’s right hand inside the 3D scene.
2. Scenario #2 (Mirror). This shows the virtual dentist
inspecting the oral cavity by picking the dentist’s
mirror from the tray and approaching towards the
patient’s oral cavity.
3. Scenario #3 (Syringe). This shows the virtual dentist
performing injection by picking the syringe from the
tray and approaching towards the patient’s oral
cavity.
4. Scenario #4 (Drill with no sound). This shows the
virtual dentist picking the drill and approaching
towards the patient’s oral cavity with no sound of
the drill.
5. Scenario #5 (Drill with sound). This shows the
virtual dentist picking the drill. The drill makes the
characteristic dental drill sound when approaching
towards the patient’s oral cavity.
Participants will be exposed to the virtual dental sce-
narios in a gradual manner. To give the participants a
gradual and optimal VRET, participants will be encour-
aged to rate their anxiety every 35 seconds following
immersion with each VR scenario exposure by means of
SUDS [39]. The general rule applied during exposure
therapy is that the exposure is continued until the sub-
jective score of the patient is reduced to less than 50 %
[44].The VRET which we are planning to use in the
current experiment has only a limited set of stimuli.
Accordingly, we have decided to have a safe cut off of
≤2 SUDS scores before moving to the next VR scenario.
This criterion was earlier applied in a similar study [17].
The exposures with scenario 1, 2, 3, 4 and 5 are repeated
p,q,r,s and t times respectively until SUDS score of ≤2 is
achieved. For instance, when participant reaches ≤2
SUDS with VR scenario of sitting idle on the dental chair
then the next VR scenario of inspecting the oral cavity
with a dental mirror is introduced. In subsequent ses-
sions, the intensity of VR experiences will be progres-
sively increased from a less threatening scenario to a
more threatening scenario to make the simulation more
realistic while focusing on areas of particular stress. For
example, if a dental phobic participant report a fear of
drills, the exposure is progressively increased from
Scenario-1 (less fear evoking –‘Sitting in the dental
chair’) to Scenario-5 (more fear evoking –‘Drill with
sound’). To this end, situational cues that are simulated
with VR scenarios are presented by the therapist in a
well-controlled manner. During the simulated dental
procedure participants will be asked to keep their mouth
open similar to real dental experience from Scenario #2
(Examination with mirrors) through Scenario #5 (Drill
with sound) and are advised to follow the instructions
of the researcher, for example ‘to open their mouth
really wide’. The added stimulus such as keeping the
mouth open will be standardized and applied to all
the participants. Participants will receive the therapy
in one long session for 150 minutes with a 10-min
break/s to avoid simulator sickness. If the participant’s
SUDS rating has not decreased to 2 with any of the
VR scenarios within 30 minutes of exposure the re-
searcher will continue with the next VR scenario. The
session will be video recorded for future validations
and analysis of the subject’s body response during the
VRET exposure.
Only verbal guidance and exposure techniques will be
used on the participants during VRET. There will be no
relaxation or other CBT-based interventions during
therapy. Participants will be instructed to become as in-
volved as possible and focus on their most frightening
stimuli of the particular part of the virtual environment
(describing the situation, any strange sensations and
their feelings). This will be done to avoid dissociation
from the VR experience. During the simulated treat-
ment, real-time recording of the psychophysiological pa-
rameters (HR) will be determined to obtain more
‘objective’ measures of the physiological state of the par-
ticipants during therapy. The HR responses obtained
with different cues (Idle, Mirror, Syringe, Drill with no
sound and Drill with sound) in this phase will be com-
pared with the baseline phase (No display) to study the
HR variations. The subjective measures of presence,
realism and nausea (cybersickness) are recorded follow-
ing the 1st exposure of each VR scenario as shown in
Table 2.
Immediate post-therapy phase In this phase, the HR is
recorded for 10 minutes and the participants are asked
to fill out a series of self-reported measures as displayed
in Table 2 and undergo the Behavioral Avoidance Test.
The total number of VR exposures with each VR
scenario will be summed up and recorded by the re-
searcher. Also, the participants fill out the questionnaire
on over-all presence, realism and nausea (cybersickness).
After the VRET session, participants will remain in the
waiting room for 15 min before leaving. This will be
done in order to make sure that are no negative side ef-
fect of VRET a posteriori.
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One week after treatment and at intervals of 3 and
6 months, the study participants will receive question-
naires that are used to assess the participants’ current
dental anxiety scores and avoidance tendency (see
Table 1) by email.
Informational pamphlet control group (IP)
Participants in the IP group will be given three pages of
information based on that of a dental website company,
and of a fact sheet about dental anxiety from the Academy
of General Dentistry [45]. The pamphlet will contain de-
tails about the standards of care such as patient comfort,
description of dental procedures and postoperative pain
management. Participants will be seated in the same area
where they completed the screening and are given time to
review the pamphlet in detail. Also, an opportunity is
given to the participants to ask the researcher information
about dental phobia. The study participants will receive a
total of 5 assessments, T0, T1, T2, T3 and T4 similar to
VRET intervention group.
Following interventions, the participants of both the
groups are told that if they have any question/s about
their condition, they can call a telephone helpline that
facilitates patient access to information and address any
questions they might have (between 08:00 to 17:00 from
Monday to Friday).
Sample size
Since the approach of the study is novel, there is scanty
comparable research available to use for a sample size
calculation. We used the difference between two inde-
pendent means’ for sample estimation (independent-
samples t-test). In a previous study [46] the response
within each subject group was normally distributed with
standard deviation (MDAS) 4.22. If the true difference in
the experimental and control means (MDAS) is 6, we
will need to study 12 experimental subjects and 12 con-
trol subjects to be able to reject the null hypothesis that
the population means of the experimental and control
groups are equal with probability (power) 0.9. The Type
I error probability associated with this test of this null
hypothesis is 0.05. Since drop-outs are unavoidable when
collecting follow-up data, the sample number needs to
be adjusted for the estimated drop-out rate. We are esti-
mating a drop-out rate of 15 % in this study. Adjusting
the sample for 15 % drop-out and 10 % for VR crash re-
sults in sample of 30 participants (15 experimental and
15 control participants).
Data analysis
The analyses will be performed based on the Consolidated
Standards of Reporting Trials (CONSORT) statement re-
garding e-health [47]. An independent biostatistician will
carry out the statistical analysis using SPSS 20.0.The
recorded data will be labelled so that the biostatistician
will not be able to distinguish between the two groups. All
data will be analyzed using an intention-to-treat analysis.
We will also conduct a per protocol analyses. Descriptive
statistics will be calculated, whereas discrete variables will
be summarized by frequencies or proportions. Continuous
variables will be reported as means and standard devia-
tions or medians and range (depending on the measure-
ment level of the variables). Data will be checked for
differences at T0, T1, T2, T3 and T4 between the VRET
and informational pamphlet group using independent
samples t-test. Between-group changes at post treatment
will be calculated by using a 2 (pre-treatment/post-treat-
ment) × 2 (VRET/Informational pamphlet) repeated mea-
sures MANOVA. Post hoc comparisons will be applied if
clarification of the main effects of the MANOVA is
needed. Effect sizes between the groups will be calculated
with Hedges’ g. Clinical significance change analyses as de-
scribed by Jacobson and Truax [48] will be conducted to
determine whether the changes from pre-test to post-test
are clinically significant [48]. Missing data analysis will be
performed and the reason for non-adherence will be
registered.
The continuous monitoring of HR data will help us
determine whether the physiological changes diminish
following multiple exposures with each scenario (sug-
gestive of habituation-Reliability of therapy).
To evaluate the correlation between subjective mea-
sures of VR experience (presence, realism, nausea) with
objective measure of HR during each VR scenario, only
the first exposure measures will be considered to elimin-
ate the order effects as shown in Table 2.
Since the baseline physiology levels will vary widely
between individuals, we will be determining the percent-
age change from baseline HR during the first exposure
of each VR scenario for analyses rather than considering
the absolute values. The percentage change of heart rate
(%HR) will be calculated as follows:
%HR ¼ MeanVR −MeanBaselineð Þ=MeanBaseline;
 100
where,
MeanVR: Mean of HR during the VRET of 1st expos-
ure of each VR scenario, and
Mean Baseline: Mean of HR during baseline phase of
VRET session.
This will help us to compare and correlate between:
1. Self-reported subjective scores (SUDS) and
Objective scores (%HR during first VR exposure of
each scenario) of anxiety. Determines the validity of
HR (how well do self-report scores correlate with
physiological measure of HR).
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2. Subjective measures of presence and the objective
scores (%HR).
3. Subjective measures of presence and realism.
4. Objective scores (%HR) and subjective realism
measures.
5. Objective scores (%HR) and subjective cybersickness
(nausea) measures.
The association between measures will be determined
using the Pearson correlation coefficient.
Discussion
The design of this randomized clinical trial offers
pathways to address the efficacy of VRET in the
treatment of long term trait dental anxiety. There-
fore, we developed (KR, ADJ and MB) a VRET de-
vice based on exposure therapy models and will be
testing the efficacy of this intervention among people
with dental phobia immediately after therapy, 1 week,
3 months and 6 months post therapy, and will be
comparing with the results of an informational
pamphlet intervention.
In recent years VRET has become a viable treatment
alternative for in vivo exposure therapy as evidence
based treatment for specific phobias with the advantage
of allowing patients to face their fears in a controlled
and thus safe, environment. Patients may not feel the
anticipatory fear of getting hurt as they are aware that
the VRET simulation is purely virtual and that these
situations can be stopped, paused, restarted as well as re-
peated, whenever, for as many times as deemed neces-
sary [10]. Accordingly, patients’ acceptance of VRET
could be relatively high.
Another important advantage of the application of
VRET for dental phobia is that it may not require spe-
cialized training and the entire exposure process can be
completed by a computer in the safety and privacy of
the practitioner’s office [10]. To this end, the study is a
feasibility study. If proved successful, the VRET device
can be rendered by any dental auxiliaries in a general
dental practice which could make it a cost-effective solu-
tion. For example, because VR technology has applica-
tions in telemedicine, in which diagnosis and treatment
can be administered from a distant site [49]. This may
make VRET applicable in rural dental clinics, in which
the therapist might not be available at long distances
and the therapist views on a monitor with which the
subject is interacting, and comment appropriately and
therapeutically.
The strengths of our study design include randomized
group allocation, use of validated standardized assess-
ments and a long term follow-up. A limitation of the
present study is the absence of IVET as gold standard
control group. Yet, it is hoped that the findings of this
study will provide evidence in support of the efficacy of
VRET and therefore will be an important step in the
treatment of dental phobia in the setting of the dental
practice.
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